文献速递慢性肾脏病遗传性与小管间质肾病

SGLT2抑制剂用于常染色体显性多囊肾病——填补证据空白

SGLT2 inhibition for patients with ADPKD - closing the evidence gap.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

SGLT2抑制剂在慢性肾脏病中具有独立于降糖的肾脏保护作用,但关键试验排除了常染色体显性多囊肾病(ADPKD)等特定人群。该综述总结SGLT2i在ADPKD中的现有证据,指出临床疗效数据缺乏与疾病特异性安全性顾虑并存,亟需充分把握度的临床试验。

要点

  • ADPKD患者被 pivotal 试验排除,SGLT2i 在此人群的疗效与安全性证据不足。
  • 临床前模型结果不一致,且缺乏临床疗效数据,是当前使用的主要障碍。
  • 多个地区正在开展或计划开展ADPKD的SGLT2i临床试验,亟需充分把握度的研究。

核心结论

  • ADPKD患者目前被排除在SGLT2i这一有前景的治疗机会之外,亟需专门临床试验验证。

研究设计与样本

  • 综述,总结SGLT2i在ADPKD患者中的现有知识并概述正在开展和即将启动的临床试验项目。

主要发现

  • SGLT2i在慢性肾脏病中显示独立于血糖的肾脏保护作用,但关键试验排除了ADPKD等特定人群。
  • ADPKD缺乏强效治疗手段,SGLT2i在该人群的应用备受关注。
  • 临床前模型结果不一致、缺乏临床疗效数据及潜在疾病特异性安全性顾虑,目前阻碍SGLT2i用于ADPKD。

临床怎么用

  • 目前不应将SGLT2i常规用于ADPKD患者,应等待专门临床试验结果。
  • 关注正在开展和即将启动的ADPKD SGLT2i临床试验,以指导未来临床决策。

局限性

  • 综述未提供ADPKD患者使用SGLT2i的临床疗效数据。
  • 临床前模型结果不一致,缺乏疾病特异性安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Inhibitors of the sodium-glucose cotransporter 2 (SGLT2i) were originally developed to treat diabetes mellitus but have shown important renoprotective benefits independently from blood glucose levels. SGLT2i have thus become an important addition to the therapeutic armamentarium to treat patients with chronic kidney disease. However, specific patient populations were excluded from the pivotal trials, for instance patients with very low eGFR, patients on dialysis, kidney transplant recipients, and patients with autosomal dominant polycystic kidney disease (ADPKD), the most common genetic kidney disorder. Considering the lack of potent treatment modalities in ADPKD, the use of SGLT2i in this patient population would be of major interest. However, the combination of inconclusive results from preclinical models with the lack of clinical efficacy data and potential disease-specific safety concerns currently exclude patients with ADPKD from this promising therapeutic opportunity. This results in an urgent need for adequately powered clinical trials examining SGLT2i in ADPKD. This review summarizes the current knowledge on SGLT2i in this specific patient population and outlines running and upcoming clinical trial programs in different geographic regions aiming to make SGLT2i accessible to patients with ADPKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Müller RU, Guerrot D, Chonchol M, et al. SGLT2 inhibition for patients with ADPKD - closing the evidence gap. Nephrol Dial Transplant. 2025. PMID: 40199734. doi:10.1093/ndt/gfaf061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。